Skip to content
Screener

OptimizeRx OPRX Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$29.2MBeat by $5.4M
EPS$0.24Beat by $0.21
Revenue estimate$23.8M
EPS estimate$0.03

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$21.6M
EPS estimate$0.19

Financials

Q2 2025

Income statement

See full
Revenue$29.2M+2,307%
Gross profit$18.6M+416%
Operating income$3.2M+186%
Net income$1.5M+138%
EPS (diluted)$0.08+136%

Balance sheet

See full
Cash & equivalents$16.6M+10.9%
Total debt$29.0M-19.7%
Total equity$119.3M-1.4%
Total assets$169.3M-2.1%

Cash flow

See full
Operating cash flow$4.6M+483%
CapEx$10.0K-77.8%
Free cash flow$4.6M+518%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$238.59M+30.6%
Enterprise value$250.98M+23.1%
P/S2.3×-1.7×

Profitability

See full
Gross margin64.4%+33.3pp
Net margin-9.4%-4.1pp
FCF margin9.9%—

Returns & leverage

See full
Return on equity-8.2%-2.6pp
Debt / equity0.2×-0.1×
Current ratio2.6×-0.5×

Segments

By product

See full
Solutions Sold On A Commissions Bases, Agent Revenue Recognized On A Net Basis$3.0M—

FAQ

When did OptimizeRx report Q2 2025 earnings?
OptimizeRx (OPRX) reported Q2 2025 earnings on August 7, 2025 after market close.
What were OptimizeRx's Q2 2025 revenue and EPS?
OptimizeRx reported revenue of $29.2M and eps of $0.24 for Q2 2025.
Did OptimizeRx beat estimates in Q2 2025?
Revenue beat the consensus estimate of $23.8M by $5.4M. EPS beat the consensus estimate of $0.03 by $0.21.
How did OptimizeRx's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 55.2% from $18.8M a year earlier and eps grew 1100.0% from $0.02.
Where can I find OptimizeRx's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001448431-25-000010) and the 10-Q periodic report (0001448431-25-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.